Sorrento keeps coming up with BETTER treatments! Better safety. Better efficacy. "Compared to its commercial competitors, A166 demonstrated a better safety profile in the initial study and potentially better efficacy, as shown in the overall response rate (ORR) of 71.4% (A166) at 6.0 mg/kg vs DS-8201, which has an ORR of 60.9% (DS-8201) at 5.4 mg/kg."
Focusing on the disease and treatments and not on Sorrento per se to start with, the info I can find on the web about HER2 equivocal breast cancers is itself, for me at any rate, unclear: answer #1, simply reclassify as negative, and answer #2, yes maybe it will respond to HER2 positive type treatment. I am impressed, however, by "advanced" here, that may mean stage 3-4. So imagine stage 4 equivocal here... After all, the first recommended course here was Herceptin plus the usual other chemo, but the second one was replace Herceptin by Kadcyla, which is the monoclocal antibody Herceptin combined with some chemo... Yes, here is Sorrento's news release (pertaining to Herceptin delivery): https://www.globenewswire.com/news-release/2021/06/04/2242297/0/en/Sorrento-Announces-Positive-Results-From-Its-License-Partner-Kelun-on-a-Phase-I-Study-of-Safety-and-Pharmacokinetics-of-A166-a-Novel-HER2-ADC-for-Advanced-HER2-Positive-Breast-Canc.html In case you want to know, Herceptin can have a negative side effect in causing the patient to faint when she gets home and hit her head against the wall, so if Sorrento can do better than that, that will be one positive thing right there. That was the end of chemo right then and there.
News 
Market Data 
Discover 
